Futura Medical CEO James Barder on Futura’s 2024 strong growth, maiden profit and 2025 plans
15 April 2025
Futura Medical announces enhanced Eroxon Gel for ED and female sexual dysfunction product
04 November 2024
Futura Medical achieves milestone with first profit as it eyes US Eroxon launch
10 September 2024
Futura Medical targets global expansion with Eroxon, eyeing profitability in 2024
10 April 2024
Futura Medical marks pivotal year with first meaningful revenue from Eroxon sales
07 February 2024
Futura Medical continues global expansion with Latin America announcement
07 November 2023
Proactive Investor Video
September 2023
Futura Medical PLC - Interim Results 2023
September 2023
Fireside Chat with James Barder, CEO of Futura Medical
July 2023
Futura Medical "absolutely delighted" with US commercialisation agreement
18 July 2023
Futura Medical in discussions with US partners after gaining FDA approval
June 2023
Futura Medical debuts Eroxon in UK and says "more launches coming"
April 2023
Futura Medical expects FDA approval for topical ED treatment during Q2
March 2023
Futura Medical "on track" for launch in H1 2023
December 2022
Fireside chat - Dr Sidney Glina & Dr Wayne Hellstrom
13 December 2022
Futura Medical cheers a "very productive six months, delivering on strategic objectives"
13 September 2022
Futura Medical hails positive phase III results as it prepares for US FDA sign-off for ED gel
31 August 2022
Futura Medical hails positive phase III results as it prepares for US FDA sign-off for ED gel
Futura Medical delighted with Cooper Health deal for MED3000
24 May 2022
Futura Medical delighted with Cooper Health deal for MED3000
Futura Medical PLC "in a good place" as it moves towards launch of MED3000
26 April 2022
Futura Medical PLC "in a good place" as it moves towards launch of MED3000
Futura Medical signs South Korean licensing deal for erectile dysfunction gel MED3000
23 March 2022
Futura Medical signs South Korean licensing deal for erectile dysfunction gel MED3000
Futura Medical PLC reaches licensing deal for erectile dysfunction gel in Brazil and Mexico
31 August 2021
Futura Medical PLC reaches licensing deal for erectile dysfunction gel in Brazil and Mexico
Futura Medical’s CEO discusses £12m fundraising for MED3000
17 May 2021
Futura Medical’s CEO discusses £12m fundraising for MED3000
Futura Medical mark 'very busy year' with three landmark steps for erectile dysfunction gel MED3000
14 April 2021
Proactive Investor interview with James Barder
Futura Medical 'at final administrative stages of getting approval' for MED3000 in Europe
19 March 2021
Proactive Interview with Ken James Futura Medical 'at final administrative stages of getting approval' for MED3000 in Europe
Futura Medical Announces Investment and Joint Collaboration to Commercialise MED3000 in China and South East Asia
04 March 2021
Futura Medical Announces Investment and Joint Collaboration to Commercialise MED3000 in China and South East Asia
Futura Medical announce regulatory and commercial progress on erectile disfunction gel
22 October 2020
James Barder Interview with Proactive Investor
Futura Medical gets set to begin formal approval steps for erectile dysfunction drug
16 September 2020
James Barder talks to Proactive Investor
Futura Medical assessing commercialisation options for CBD100
03 August 2020
James Barder interview with Proactive Investor
Futura Medical's Ken James updates on EU and US regulatory progress for MED3000
13 July 2020
Ken James interview with Proactive Investor
Regulatory submissions for MED3000 remain on track
26 June 2020
James Barder, Chief Executive interview with Proactive Investor’s Andrew Scott
Full Year Results for the year ended 31 December 2019
01 April 2020
James Barder, Chief Executive interview with Proactive Investor’s Andrew Scott
Interview with Executive Director and Head of R&D - EU regulatory update and analysis of FM57
01 January 2020
Ken James speaks to Proactive Investor’s Andrew Scott following positive initial discussions with EU regulators after an extensive internal evaluation of the clinical data from the Phase 3 study (“FM57”).
Interview with Executive Director and Head of R&D - Phase III Results
02 December 2019
Ken James speaks to Proactive London's Andrew Scott following the read-out from the phase III clinical trial of its erectile dysfunction gel.
Fireside chat - Ken James & Dr Wayne Hellstrom
12 November 2019
Fireside chat with Ken James & Dr Wayne Hellstrom
Interview of CEO – Interims
02 September 2019
James Barder caught up with Proactive London's Andrew Scott to talk through the company's interim results.
Introduction to Futura
James Barder introduces Futura and its lead product MED2005
Fireside Chat
01 February 2019
Fireside chat with Professor David Ralph and Ken James
Milestone for Futura Medical
Interview of Ken James, Head of R&D, by Proactive Investors in which he discusses milestone for Futura Medical
On track with Phase 3 trial
Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses their Phase 3 trial
New safety data on lead treatment
Interview of Ken James, Head of R&D, by Proactive Investors in which he discusses new safety data on lead treatment
Futura Medical doses first patient in Phase 3 study
Interview of Angela Hildreth, FD and COO, by Proactive Investors in which she discusses the first patient in its Phase 3 clinical study of MED2005
MED2005 treatment clinical trial set to begin
Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses MED2005
Phase 3 study kick off
Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the lead asset MED2005
MED2005 Clinical Programme Update
Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the first Phase 3 efficacy trial for MED2005
Preliminary results for the year ended 31 December 2017
Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the progress across Futura's portfolio of products.
MED2005 interview
Interview of James Barder, Chief Executive, by Proactive Investors in which James discusses the recent article published by the Journal of Sexual Medicine.
MED2005 update
Interview of James Barder, Chief Executive, by Proactive Investors in which James discusses the start of the PK study and provides a regulatory, clinical and commercial update.
Positive market research data on MED2005
Interview of James Barder, Chief Executive, by Proactive Investors in which James discusses the positive market research data on MED2005 announced on 16 October 2017.
Interim results
Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the Interim results for the period ending 30 June 2017 including the Phase 3 programme for MED2005 and the strategy for CSD500.
Church and Dwight license termination
Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the change of priorities which sees Futura Medical distributor terminate licensing agreement.
Critical step in the development of MED2005
Video Interview of James Barder discussing a 'critical step' in the development of MED2005
Preliminary results
Video Interview of James Barder discussing the Preliminary results for the year ended 31 December 2016
Significant interest for MED2005
Video Interview of James Barder discussing the significant interest for MED2005, Futura’s erectile dysfunction gel based on Ipsos research
UK licensing agreement
Video Interview of James Barder discussing the UK licensing agreement for its pain relief gel TPR100 and the launch of CSD500 in Saudi Arabia
Futura Medical confirm US Food & Drug Administration agreement 'hot on heels' of EU regulatory steps
22 March 2021
Interview with Ken James Futura Medical confirm US Food & Drug Administration agreement 'hot on heels' of EU regulatory steps